

## S 252

### Medicare Drug Savings Act of 2017

**Congress:** 115 (2017–2019, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Feb 1, 2017

**Current Status:** Read twice and referred to the Committee on Finance.

**Latest Action:** Read twice and referred to the Committee on Finance. (Feb 1, 2017)

**Official Text:** <https://www.congress.gov/bill/115th-congress/senate-bill/252>

## Sponsor

**Name:** Sen. Nelson, Bill [D-FL]

**Party:** Democratic • **State:** FL • **Chamber:** Senate

## Cosponsors (15 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Baldwin, Tammy [D-WI]	D · WI		Feb 1, 2017
Sen. Blumenthal, Richard [D-CT]	D · CT		Feb 1, 2017
Sen. Brown, Sherrod [D-OH]	D · OH		Feb 1, 2017
Sen. Durbin, Richard J. [D-IL]	D · IL		Feb 1, 2017
Sen. Franken, Al [D-MN]	D · MN		Feb 1, 2017
Sen. Hirono, Mazie K. [D-HI]	D · HI		Feb 1, 2017
Sen. King, Angus S., Jr. [I-ME]	I · ME		Feb 1, 2017
Sen. Klobuchar, Amy [D-MN]	D · MN		Feb 1, 2017
Sen. Leahy, Patrick J. [D-VT]	D · VT		Feb 1, 2017
Sen. Reed, Jack [D-RI]	D · RI		Feb 1, 2017
Sen. Sanders, Bernard [I-VT]	I · VT		Feb 1, 2017
Sen. Stabenow, Debbie [D-MI]	D · MI		Feb 1, 2017
Sen. Udall, Tom [D-NM]	D · NM		Feb 1, 2017
Sen. Whitehouse, Sheldon [D-RI]	D · RI		Feb 1, 2017
Sen. Shaheen, Jeanne [D-NH]	D · NH		Mar 7, 2017

## Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Feb 1, 2017

## Subjects & Policy Tags

**Policy Area:**

Health

## Related Bills

Bill	Relationship	Last Action
115 S 3411	Related bill	Sep 5, 2018: Read twice and referred to the Committee on Finance.
115 HR 4138	Related bill	Oct 27, 2017: Referred to the Subcommittee on Health.
115 S 1511	Related bill	Jun 29, 2017: Read twice and referred to the Committee on Finance.
115 HR 1776	Related bill	Apr 5, 2017: Referred to the Subcommittee on Health.
115 S 771	Related bill	Mar 29, 2017: Read twice and referred to the Committee on Finance.

## Summary (as of Feb 1, 2017)

### Medicare Drug Savings Act of 2017

This bill requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for prescription drugs dispensed to eligible low-income individuals under the Medicare prescription drug benefit or a Medicare Advantage (MA) prescription drug plan (PDP).

Subject to civil monetary penalties, a Medicare or MA PDP sponsor must report, both to drug manufacturers and to the CMS, specified information related to the determination and payment of such rebates.

### Actions Timeline

- **Feb 1, 2017:** Introduced in Senate
- **Feb 1, 2017:** Read twice and referred to the Committee on Finance.